-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 6, 2021, Dialectic Therapeutics announced that the first-generation compound DT2216, constructed based on its proprietary new anti-apoptotic protein targeted degradation technology (APTaD), has completed the first patient administration in a phase 1 clinical trial.
Preclinical studies have shown that DT2216 can selectively induce the degradation of BCL-XL protein in cancer cells
Picture source: reference [2]
This multi-center, dose-escalating phase 1 clinical trial is aimed at patients with advanced/metastatic solid tumors and hematological malignancies, who no longer respond to approved or standard treatments
Reference materials:
[1] Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients with Relapsed or Refractory Malignancies.
[2] Pal, P.
(The original text has been deleted)